Polypill trials have been generally designed to demonstrate bioequivalence rather than differences in clinical outcomes; high quality “usual care” seen in trials limits power. Polypills are essential medicines for secondary ASCVD prevention, especially among low adherers, and the growth of polypill suggests an opening of the marketplace for these combinations.